Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its quarterly earnings data on Thursday. The biotechnology company reported $0.11 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.13 by ($0.02), reports. Corcept Therapeutics had a net margin of 22.28% and a return on equity of 51.45%. The business had revenue of $42.70 million during the quarter, compared to analysts’ expectations of $41.64 million. During the same period in the prior year, the firm posted $0.02 EPS. Corcept Therapeutics’s revenue for the quarter was up 96.8% compared to the same quarter last year.

A number of equities research analysts have weighed in on CORT shares. Piper Jaffray Companies lifted their price objective on Corcept Therapeutics from $18.00 to $24.00 and gave the company a “buy” rating in a report on Friday, September 8th. Stifel Nicolaus started coverage on Corcept Therapeutics in a report on Thursday, August 31st. They issued a “buy” rating and a $20.00 price objective on the stock. BidaskClub lowered Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 4th. Ladenburg Thalmann Financial Services set a $20.00 price objective on Corcept Therapeutics and gave the company a “buy” rating in a report on Tuesday, July 18th. Finally, Zacks Investment Research lowered Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $18.20.

TRADEMARK VIOLATION WARNING: “Corcept Therapeutics Incorporated (CORT) Issues Earnings Results” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Earnings History for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with's FREE daily email newsletter.